---
schema_version: "secwatch.filing_event.v1"
accession: "0000914121-22-002826"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2022-04-07T23:59:59+00:00"
generated_at: "2026-06-26T08:42:12.232609+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics Q3 net sales $74.0M (+3.9% YoY); GAAP EPS -$0.13, adjusted $0.03; reaffirms FY guidance

## Summary
- Net sales $74.0M (+3.9% YoY); Med Tech +28.6% driven by Auryon ($7.3M) and thrombectomy; Med Device -2.8%.
- Gross margin 52.2%, down 190bps YoY on inflation, labor, supply chain; net loss $5.0M ($0.13/sh) vs $3.5M loss prior year.
- Adjusted EPS $0.03 (incl. $4.2M CARES Act benefit); adjusted EBITDA $6.7M vs $5.4M a year ago.
- Reaffirmed FY2022 guidance: sales $310-315M, gross margin 52-54%, adjusted EPS -$0.02 to $0.02.
- Post-quarter: FDA cleared AlphaVac F18 for venous use; IDE approved for pulmonary embolism; PRESERVE prostate trial enrolled.

## SEC filing metadata
- accession: 0000914121-22-002826
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2022-04-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000091412122002826/0000914121-22-002826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000091412122002826/an57733391-8ki.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914121-22-002826
- JSON: https://secwatch.observer/filing/0000914121-22-002826.json
- Plain text: https://secwatch.observer/filing/0000914121-22-002826.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.